Skip to main content
Figure 7 | Breast Cancer Research

Figure 7

From: Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models

Figure 7

High efficacy in combination therapy of GLPG0187 and standard-of-care treatments. (A-C) GLPG0187 combined with the antiresorptive standard-of-care agent zoledronate in the MDA-MB-231-mouse bone metastasis model (Figure 6) shows efficacy on the tumor burden, tumor-induced osteolysis, and tibiae bone volume/trabecular bone volume (BV/TV) parameter measured by micro computed tomography (Μct). (D-F) GLPG0187 combined with the chemotherapeutic standard-of-care agent paclitaxel in the bone metastasis model shows efficacy on the tumor burden, tumor-induced osteolysis, and tibiae BV/TV parameter measured by μCT. Relevant doses of standard-of-care therapeutic agents were administered: zoledronate (30 μg/kg weekly subcutaneaously) , paclitaxel (20 mg/kg weekly intraperitoneally). GLPG0187 was tested at 10, 30 and 100 mg/kg, orally, twice daily either separately or in combination with the above therapeutic agents.

Back to article page